About the project

Despite the strengths of its science base, Australia has been less successful at translating research into clinical outcomes and commercial successes with the aim of improving greater health for the community within Australia and the world.

This is influenced by the lack of infrastructure for med scale ups. The gap means companies are receiving manufacturing equipment and recruiting to commence Phase II trials, but they do not have the facilities to proceed and have to take their innovations overseas, setting Australia back.

enable translational research and clinical synergies

providing capability and innovative pathways for emerging and growing start-ups

TMI@TRI recognises the gap in Australia and would enable translational research and clinical synergies by providing capability and innovative pathways for emerging and growing start-ups as they commercialise their research.

The TMI@TRI project team is seeking funding and support from Queensland and Commonwealth Governments to build the facility and enable the immediate retention of the start-up cohorts, bolster the pathway journey through enabling specialist infrastructure including medtech manufacturing; and facilitate the pipeline of new startups

TMI@TRI benefits:


Development of a national skills in MTP sector.


Contribution to national innovation, capacity building of innovation business, manufacturing and industry.


Advancement of research commercialisation and export opportunities.


Increase ‘sovereign capability’ and manufacturing capability against pandemics.


Promotes engagement with universities, research institutes, clinic and industry


Retention of medtech start-up companies in Australia


Creation of a pipeline of start-ups transitioning from TRI to TMI@TRI.


Reputation enhancement for Queensland and Australian innovation through research and commercialisation successes e.g. Gardasil HPV vaccine development as the foundation for TRI.


Providing non-existent practical cGMP training to early career researchers and SME’s and build the skilled workforce Australia currently lacks.


Creation of jobs (direct and in-direct) jobs and spin-off benefits across multiple allied industries including over 1,400 construction jobs and 200 associated jobs every year for the first five years of its operation.


Increased productivity through proximity and collaboration of the mature resources on-site.


Attracts the best scientists into Australia, who can engage in vital research and development.


Increased opportunity for Queenslanders/Australians to participate in clinical trials.